Control of the intracellular levels of prostaglandin E2 through inhibition of the 15-hydroxyprostaglandin dehydrogenase for wound healing

被引:15
作者
Choi, Dubok [1 ]
Piao, Yu Lan [2 ]
Wu, Ying [2 ]
Cho, Hoon [2 ]
机构
[1] Chungbuk Natl Univ, Coll Pharm, Dept Pharm, Cheongju 361763, South Korea
[2] Chosun Univ, Dept Polymer Sci & Engn, Kwangju 501759, South Korea
关键词
15-PGDH; Prostaglandin E-2; Scar; Thiazolidinediones; Transforming growth factor-beta; Wound healing; DERIVATIVES; 15-PGDH; ANTIBACTERIAL;
D O I
10.1016/j.bmc.2013.05.049
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Excessive scar formation is an aberrant form of wound healing and is an indication of an exaggerated function of fibroblasts and excess accumulation of extracellular matrix during wound healing. Much experimental data suggests that prostaglandin E-2 (PGE(2)) plays a role in the prevention of excessive scarring. However, it has a very short half-live in blood, its oxidization to 15-ketoprostaglandins is catalyzed by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). Previously, we reported that 15-PGDH inhibitors significantly increased PGE(2) levels in A549 cells. In our continuing attempts to develop highly potent 15-PGDH inhibitors, we newly synthesized various thiazolidine-2,4-dione derivatives. Compound 27, 28, 29, and 30 demonstrated IC50 values of 0.048, 0.020, 0.038 and 0.048 mu M, respectively. They also increased levels of PGE(2) in A549 cells. Especially, compound 28 significantly increased level of PGE(2) at 260 pg/mL, which was approximately fivefold higher than that of control. Scratch wounds were analyzed in confluent monolayers of HaCaT cells. Cells exposed to compound 28 showed significantly improved wound healing with respect to control. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:4477 / 4484
页数:8
相关论文
共 29 条
  • [1] Altintas H, 2006, ARZNEIMITTELFORSCH, V56, P239
  • [2] ANGGARD E, 1964, J BIOL CHEM, V239, P4097
  • [3] Antonov S. F., 2008, AGR SCI, V34, P426
  • [4] Inhibition of NAD+-dependent 15m-hydroxyprostagland in dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents
    Cho, H
    Tai, HH
    [J]. PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2002, 67 (06): : 461 - 465
  • [5] Thiazolidinediones as a novel class of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors
    Cho, H
    Tai, HH
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2002, 405 (02) : 247 - 251
  • [6] Clark R. A. F., 1996, MOL CELLULAR BIOL WO
  • [7] COLEMAN RA, 1994, PHARMACOL REV, V46, P205
  • [8] Cristiano N., 2009, OPEN DIABETES J, V2, P53
  • [9] Deohate PP, 2004, ASIAN J CHEM, V16, P255
  • [10] NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer
    Ding, YF
    Tong, M
    Liu, SQ
    Moscow, JA
    Tai, HH
    [J]. CARCINOGENESIS, 2005, 26 (01) : 65 - 72